70 related articles for article (PubMed ID: 12209709)
1. Is micropapillary serous carcinoma for real?
Gershenson DM
Cancer; 2002 Aug; 95(4):677-80. PubMed ID: 12209709
[No Abstract] [Full Text] [Related]
2. Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors).
Seidman JD; Kurman RJ
Cancer; 2002 Aug; 95(4):675-6. PubMed ID: 12209708
[No Abstract] [Full Text] [Related]
3. Skin metastases revealing a bilateral ovarian invasive micropapillary serous carcinoma.
Moussa A; Denguezli W; Njim L; Haddad A; Faleh R; Sakouhi M; Zakhama A
Arch Gynecol Obstet; 2008 Jul; 278(1):71-4. PubMed ID: 18066568
[TBL] [Abstract][Full Text] [Related]
4. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
5. Uterine papillary serous carcinoma: what have we learned over the past quarter century?
Goff BA
Gynecol Oncol; 2005 Sep; 98(3):341-3. PubMed ID: 16111527
[No Abstract] [Full Text] [Related]
6. Integrative tumor board: recurrence of ovarian cancer.
Knaus JV; Bugno T; Nathan D; Lagomarcino N; Labriola D; Block PB; Alvarado C; Chamness A; Block KI
Integr Cancer Ther; 2002 Dec; 1(4):392-416. PubMed ID: 14664733
[No Abstract] [Full Text] [Related]
7. Bilateral micropapillary serous carcinoma of the ovary: a case report.
Gupta R; Singh S; Nigam S
Arch Gynecol Obstet; 2007 May; 275(5):401-4. PubMed ID: 17031658
[TBL] [Abstract][Full Text] [Related]
8. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Yoshikawa K; Sato Y; Aoyama H; Hayashi T; Kushima R
Hum Pathol; 2008 May; 39(5):666-71. PubMed ID: 18339419
[TBL] [Abstract][Full Text] [Related]
9. Recurrent micropapillary serous ovarian carcinoma.
Bristow RE; Gossett DR; Shook DR; Zahurak ML; Tomacruz RS; Armstrong DK; Montz FJ
Cancer; 2002 Aug; 95(4):791-800. PubMed ID: 12209723
[TBL] [Abstract][Full Text] [Related]
10. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
Gershenson DM; Sun CC; Lu KH; Coleman RL; Sood AK; Malpica A; Deavers MT; Silva EG; Bodurka DC
Obstet Gynecol; 2006 Aug; 108(2):361-8. PubMed ID: 16880307
[TBL] [Abstract][Full Text] [Related]
11. Microdissection-based mutational genotyping of serous borderline tumors of the ovary.
Krishnamurti U; Sasatomi E; Swalsky PA; Jones MW; Finkelstein SD
Int J Gynecol Pathol; 2005 Jan; 24(1):56-61. PubMed ID: 15626917
[TBL] [Abstract][Full Text] [Related]
12. Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern.
Laurent I; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
Ann Surg Oncol; 2008 Dec; 15(12):3561-6. PubMed ID: 18820973
[TBL] [Abstract][Full Text] [Related]
13. Uterine papillary serous carcinoma: a new paradigm for treatment?
Annunziata CM; Kotz HL
Cancer; 2009 Aug; 115(16):3594-6. PubMed ID: 19452535
[No Abstract] [Full Text] [Related]
14. Borderline epithelial tumors of the ovary.
Hart WR
Mod Pathol; 2005 Feb; 18 Suppl 2():S33-50. PubMed ID: 15761465
[TBL] [Abstract][Full Text] [Related]
15. High-dose rate brachytherapy for Stage I/II papillary serous or clear cell endometrial cancer.
DuBeshter B; Estler K; Altobelli K; McDonald S; Glantz C; Angel C
Gynecol Oncol; 2004 Aug; 94(2):383-6. PubMed ID: 15297176
[TBL] [Abstract][Full Text] [Related]
16. Uterine papillary serous carcinoma: patterns of failure and survival.
Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
[TBL] [Abstract][Full Text] [Related]
17. Current issues in the pathology of ovarian cancer.
Rabban JT; Bell DA
J Reprod Med; 2005 Jun; 50(6):467-74. PubMed ID: 16050571
[TBL] [Abstract][Full Text] [Related]
18. [Serous micropapillary invasive carcinoma. Case report on both ovaries].
Espinosa de los Monteros Franco VA; Padilla Rodríguez AL
Ginecol Obstet Mex; 2007 Nov; 75(11):682-6. PubMed ID: 18697443
[TBL] [Abstract][Full Text] [Related]
19. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
[TBL] [Abstract][Full Text] [Related]
20. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
